Fund moves
4.4%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NRIX · NASDAQ · Pharmaceutical Preparations
Nurix Therapeutics (NRIX) · oqro.io/stocks/NRIX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$12.85−0.75 (−5.51%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Nurix Therapeutics is on record in SEC filings since 2006.
Since 2021, Nurix Therapeutics insiders reported 0 open-market purchases and 163 sales on Forms 4 and 5.
In the last 90 days, 4 insiders of Nurix Therapeutics (NRIX) reported 12 open-market sales worth $1.53M in total on SEC Form 4. The largest seller by value was Christine Ring, with $670K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Nurix Therapeutics (NRIX) was disclosed by a member of Congress in the last 12 months.
Nurix Therapeutics's next results are expected on Jan 26, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−16.2% (−$2.48) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $15.33 on Nov 20, 2025 to $12.85 on Nov 20, 2026 (−16.2%). Disclosed in this range: 1 insider trade, 11 pre-arranged insider sales, 0 Congress trades, and 21 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Brisbane, Ca.
Last 12 months
−16.2%
Market value
$1.54B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 18.9M shares sold short (15.8% of shares outstanding), −8.1% vs the previous count, 7.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$84M
+54.0% vs the year before
Net income, fiscal 2025
−$264M
A loss for the year
Shares outstanding
109M
As of Sep 30, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Nurix Therapeutics reported 0 open-market purchases and 163 sales since 2021; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $1.53M12×12 trades |
| 2025 | — | $884K19×19 trades |
| 2024 | — | $3.08M36×36 trades |
| 2023 | — | $280K16×16 trades |
| 2022 | — | $203K14×14 trades |
| 2021 | — | $4.92M66×66 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Nov 13, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeOn the public record for Nurix Therapeutics over the 12 months to Nov 20, 2026: 3 clinical trials.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Against the S&P 500 over the year
Who holds it
Things to keep in mind
Records
Since Nov 17, 2025, NRIX is up 6.3% and the index fund is up 7.5%: 1 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much NRIX moves
Beta 1.2 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 248 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Revenue
$673M
+8426.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$370M
This quarter $614M, a year earlier −$60.1M
Net debt
—
Debt —, cash $720M, at Aug 31, 2026
Net income, last 12 months
$295M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 13, 2026.
Revenue and earnings history, 7 fiscal yearsEarnings dates and the stock's moves
Last results
Oct 13, 2026
More than 30 days ago
Next results, expected
Jan 26, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Nurix Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Nurix Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
1 active phase 3 trial and 2 active phase 2 trials led by this company, mostly in b-cell lymphoma, chronic lymphocytic leukemia (cll). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Fiscal year Dec 1, 2024 to Nov 30, 2025, from the annual report filed Jan 28, 2026. Read the filing
−1.0% on the year before ($54.5M)
$0 the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with leading ligase expertise, we have built a significant advantage in translating the science of protein degradation into clinical advancements with the aim of establishing degrader-based treatments at the forefront of patient care.
And 16 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Jan 28, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
3 certified in FY2026 Q3, vs 7 a year earlier. 3 positions in total, median offered wage $130K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Latest annual report filed Jan 28, 2026, compared with the one filed Jan 28, 2025. Read the filing
From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business or financial statements. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors.
Source: SEC EDGAR, Form 10-K filed Jan 28, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 49.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (23.6% on ATS, 25.6% with other brokers), above its 26-week average of 46.3%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (12.4%), INTELLIGENT CROSS LLC (11.2%), SIGMA X2 (10.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.